Globus Medical Q3 profit beat estimates on U.S. spine growth

Globus Medical

06/11/2025 22:28

Overview

Globus Medical Q3 sales rose 22.9% yr/yr, beating analyst expectations

Adjusted EPS for Q3 beats consensus, growing 42.6% yr/yr

Company executed $40 mln in share repurchases, totaling $255.5 mln in 2025

Outlook

Company raises 2025 revenue guidance to $2.86-$2.90 bln from $2.80-$2.90 bln

Globus Medical expects 2025 non-GAAP EPS of $3.75-$3.85, up from $3.00-$3.30

Company anticipates Nevro acquisition to be accretive to 2025 earnings

Result Drivers

US SPINE GROWTH - 10% growth in US Spine business contributed to overall revenue increase, per CEO Keith Pfeil

NEVRO ACQUISITION - Nevro business exceeded expectations, supporting integration strategy and future growth

SYNERGY CAPTURE - Improved gross margins and operating expenses due to synergy capture from mergers and acquisitions

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
Beat
$769 mln
$734.35 mln (12 Analysts)
Q3 Adjusted EPS
Beat
$1.18
$0.78 (12 Analysts)
Q3 EPS
$0.88
Q3 Net Income
$119 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 7 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Globus Medical Inc is $78.00, about 21.1% above its November 5 closing price of $61.51

The stock recently traded at 17 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nGNX6lVQxn

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)